Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | HTR2C | P28335 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | PLAT | P00750 | 1/20 | 0.46 |
| ▸ | DHFR | P00374 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16752384 | 0.90 | TSHR (0.65) | TSHRALDH1A1HSD17B10CA1CA2 | |
| SCHEMBL15019745 | 0.87 | TSHR (0.61) | TSHRALDH1A1HSD17B10CA1CA2 | |
| SCHEMBL9271467 | 0.87 | TSHR (0.60) | TSHRHTR2CALDH1A1HSD17B10POLB | |
| SCHEMBL1790478 | 0.85 | TSHR (0.59) | TSHRALDH1A1HSD17B10CA1CA2 | |
| SCHEMBL4431279 | 0.84 | HTR2C (0.55) | TSHRHTR2CALDH1A1HSD17B10PLAT | |
| SCHEMBL3585587 | 0.83 | TSHR (0.56) | TSHRALDH1A1HSD17B10CA1CA2 | |
| Hydrochloric Acid SCHEMBL5729720 | 0.82 | HTR2C (0.56) | TSHRHTR2CALDH1A1HSD17B10PLAT | |
| Hydrochloric Acid SCHEMBL7086185 | 0.82 | TSHR (0.43) | TSHRALDH1A1HSD17B10CA1CA2 | |
| SCHEMBL5386421 | 0.82 | TSHR (0.62) | TSHRALDH1A1HSD17B10CA1CA2 | |
| SCHEMBL28353512 | 0.81 | TSHR (0.57) | TSHRALDH1A1HSD17B10CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118063458-A | Novel dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-110621676-B | Dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-108290896-B | 2-phenyl-3, 4-dihydropyrrolo [2,1-F ] [1,2,4] triazinone derivatives and uses thereof | 托帕杜制药公司 | 2021-09-28 | — | — | CN | disclosed |
| CN-110621676-A | Novel dual mode of action of soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof | 托帕杜制药公司 | 2019-12-27 | — | — | CN | disclosed |
| CN-108290896-A | 2- phenyl -3,4- pyrrolin as phosphodiesterase inhibitors simultaneously [2,1-F] [1,2,4] triazone derivatives and application thereof | 托帕杜制药公司 | 2018-07-17 | — | — | CN | disclosed |
| US-8431709-B2 | Acylation reaction of hydroxyl group | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-04-30 | — | — | US | disclosed |
| US-20100249422-A1 | ACYLATION REACTION OF HYDROXYL GROUP | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249422-A1 | ACYLATION REACTION OF HYDROXYL GROUP | ADH5, ADH1A, ACADM | TSHR 2272/4885HTR2C 3295/4885ALDH1A1 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.